
BiolInvent Q2 2025 - Narrowed Focus on BI-1206 and BI-1808

Redeye comments on BiolInvent's Q2 report 2025. New positive results with BI-1206 in solid tumours and Non-Hodgkin lymphoma and with BI-1808 in T-cell lymphoma were presented. A pause of BI-1607 and BI-1910 was announced yesterday as the company focuses on late- to mid-stage development of BI-1206 and BI-1808.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BiolInvent Q2 2025 - Narrowed Focus on BI-1206 and BI-1808